HNP1-3, Human, mAb D21
Human neutrophil defensins (alpha-defensins) belong to the family of cationic trisulfide-containing microbicidal peptides. Besides microbicidal, the peptides exert chemotactic, immunomodulating and cytotoxic activity and participate in host defense and inflammation. Defensins are important effector molecules against enveloped viruses, bacteria, fungi and protozoa, and protein concentrations ranging from 0.5 to 5 μM were shown to kill a wide range of microbes in vitro. Defensins have the ability to attack susceptible microorganisms and destroy the structure of target cell membranes. Several members of each defensin family were shown to act as microbicides against distinct Gram-negative and Gram-positive bacteria, as well as fungi and viruses in vitro.
Azurophilic granules of neutrophils contain Human Neutrophil Peptide (HNP) 1-4, which are highly homologous. The three principal human defensins, HNP 1-3, are unique to neutrophils and- account for about 99% of the total defensin content of these cells. Defensins HNP 1-3 are almost exclusively expressed in neutrophils, therefore it is considered a neutrophil cell marker. Measured amount of defensins is 3-5 microgram per million human neutrophils. When treated with HNP the outer membrane of Escherichia coli becomes permeable. This permeabilization furthermore coincided with the cessation of RNA, DNA and protein synthesis, and with a decreased bacterial viability Defensins are relatively resistant to proteolysis, low pH and boiling. Activation of neutrophils leads to rapid release of HNP. HNP can be measured in plasma and other body fluids during infection and inflammation. In normal plasma very low levels of HNP are present. Activation of polymorphonuclear leukocytes (PMN) in plasma, as occurs during clotting of blood, leads to a rapid release of HNP.
Anti HNP 1-3 antibody clone D21 recognizes natural HNP 1-3 in biological solutions by means of ELISA in tissue sections and leukocyte smears fixed with ethanol, methanol/acetone or paraformaldehyde, in flow cytometry analysis of human neutrophils stained by cell permeabilization method and in Western-blotting (non-reduced). Furthermore the antibody is cross reactive with Rhesus monkey and cynomolgous macaques HNP1-3.
FC: Cells were fixed and permeabilized, incubation with primary antibody for 30 min.
FS: In vitro:0.5ug/ml, 30min -24h at 37 °C
IF: 1% formaldehyde fixed cells were stained with 5 µl Ab/million cells for 15 min.
P: Formalin fixed sections were deparaffinized and blocked with 1% hydrogen peroxide and serum or 5%BSA
W: Blots blocked with 10% serum for 30'. Primary antibody 2h RT 1:100 in TBS/0.01% tween-20
You may also like…
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA